Full Breakdown
Trump Administration Ends Federal Medicaid and CHIP Funding for Gender-Affirming Care of Minors
8/13/2026, 12:56:54 AM
Core Policy Change
On August 11, 2026, the Centers for Medicare & Medicaid Services (CMS) issued a final rule that bars the use of federal Medicaid dollars for “sex-rejecting procedures”—including puberty blockers, cross-sex hormones, and gender-transition surgeries—for children under 18. The rule also prevents Children’s Health Insurance Program (CHIP) plans from covering the same procedures for individuals under 19. A six-month transition period will allow beneficiaries already receiving hormone therapy to continue receiving coverage. The restrictions take effect on October 12, 2026 (Medicaid) and October 13, 2026 (CHIP).
Background & Context
The rule follows a January 2025 executive order directing agencies to stop funding “transition” treatments for minors and a December 2025 proposal that cited “significant evidence gaps” and safety concerns. Earlier this year, a federal judge blocked an attempt to deny hospitals federal payments for unrelated services if they provided gender-affirming care. The administration’s approach aligns with other recent policies affecting transgender athletes and passport gender markers.
Data & Statistics
- The Congressional Budget Office estimated federal spending of roughly $100 million on gender-transition treatments for Medicaid-insured minors from 2019-2023.
- The rate of gender-related surgeries among Medicaid-covered 15- to 17-year-olds was 3.44 per 100,000.
- A 2024 study found less than 1 percent of minors received surgical gender-affirming care; most procedures involved puberty blockers or hormone therapy.
- At least 27 states already prohibit Medicaid coverage for gender-affirming care for those under 18.
- The administration projects the rule will reduce federal spending by about $235 million over ten years.
Official Statements & Responses
Health and Human Services Secretary Robert F. and CMS Administrator Dr. [Name] promoted the change on social media, describing the treatments as “barbaric” and asserting the policy will spare “innocent children” from harmful procedures.
Criticism & Opposition
Legal director Josh Rovenger of GLAD Law argued that “no federal law prohibits this care,” emphasizing research that deems gender-affirming treatment “effective, safe, and essential.”
Conflicting Reports & Gaps
Sources differ on the prevalence of surgical interventions. One report cites a surgery rate of 3.44 per 100,000 Medicaid beneficiaries aged 15-17, while another notes less than 1 percent of all minors receive any gender-affirming surgery. Both figures indicate surgeries are rare, but the exact magnitude remains unclear. The administration’s referenced research on “significant evidence gaps” is described only in general terms, without specific studies cited.
Verbatim Quotes
- “Children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits.” — Medicaid Services
- “We are not going to pay for our innocent children to undergo these barbaric surgeries and practices, which result in unthinkable and irreversible harm to their young bodies.” — President Donald Trump
- “No federal law prohibits this care,” — Josh Rovenger, GLAD Law
What’s Next
The rule’s effective date of October 12/13, 2026 triggers a six-month transition period for existing hormone-therapy patients. States that wish to continue covering gender-affirming care must fund it without federal matching dollars. Legal challenges from the Human Rights Campaign and other advocacy groups are expected before the rule takes effect.
